Company news

Surrozen, Inc. news in 2024

Surrozen, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

November 5, 2024

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

November 3, 2024

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

September 23, 2024

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

August 11, 2024

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

June 9, 2024

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

June 3, 2024

Surrozen Provides First Quarter 2024 Financial Results and Business Update

May 7, 2024

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

March 31, 2024

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

March 31, 2024

Surrozen Provides Corporate Update on Clinical Programs

January 17, 2024

Decks in 2024